A Phase II Study of Bevacizumab in Combination With Docetaxel and Radiation in Locally Advanced Squamous Cell Cancer of the Head and Neck.
Latest Information Update: 03 Oct 2016
At a glance
- Drugs Bevacizumab (Primary) ; Docetaxel (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- 19 Jul 2012 Planned end date changed from 1 Dec 2012 to 1 Apr 2012 as reported by ClinicalTrials.gov.
- 28 Jun 2011 Planned end date changed from 1 Jan 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.
- 27 Sep 2010 Planned end date changed from 1 Sep 2008 to 1 Jan 2011 as reported by ClinicalTrials.gov.